The childhood cancer data initiative: enabling data sharing to drive research advances and transform pediatric cancer diagnosis and treatment.

Subhashini Jagu, Jaime M Guidry Auvil, Gregory Reaman
Author Information
  1. Subhashini Jagu: Office of Data Sharing, Center for Biomedical Informatics and Information Technology, National Cancer Institute, Rockville.
  2. Jaime M Guidry Auvil: Office of Data Sharing, Center for Biomedical Informatics and Information Technology, National Cancer Institute, Rockville.
  3. Gregory Reaman: Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.

Abstract

PURPOSE OF REVIEW: With growing emphasis on data-driven research in pediatric oncology, particularly in the context of advances in molecular characterization and precision medicine, there is an urgent need for comprehensive data-sharing initiatives. This review explores how the Childhood Cancer Data Initiative (CCDI) addresses this critical need.
RECENT FINDINGS: CCDI plays a key role in enhancing pediatric cancer research by improving data integration, sharing, and collaboration. Its Molecular Characterization Initiative advances the field by leveraging detailed molecular data to inform clinical trials and therapeutic strategies. For small patient populations, such as those with rhabdomyosarcoma, CCDI's efforts in integrating data across institutions are vital for advancing risk-based treatment strategies to achieve meaningful clinical outcomes.
SUMMARY: CCDI's advancements in data sharing have profound implications for both clinical practice and research. By enabling precise diagnoses, tailoring treatments based on individual genetic profiles, and addressing the challenges associated with small patient populations, CCDI is driving transformative changes in pediatric oncology. Continued support and expansion of such initiatives are crucial to fully realizing their potential in improving outcomes for children with cancer.

References

  1. Lancet Oncol. 2019 Apr;20(4):483-493 [PMID: 30824204]
  2. Pediatr Blood Cancer. 2017 Mar;64(3): [PMID: 27748023]
  3. J Clin Oncol. 2022 Jul 10;40(20):2224-2234 [PMID: 35353553]
  4. CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49 [PMID: 38230766]
  5. Recent Results Cancer Res. 2021;218:149-173 [PMID: 34019168]
  6. J Clin Oncol. 2020 Dec 20;38(36):4227-4230 [PMID: 32946356]
  7. Pediatr Blood Cancer. 2024 Feb;71(2):e30745 [PMID: 37889049]
  8. Pediatr Res. 2023 Jan;93(2):342-349 [PMID: 35974162]
  9. Clin Cancer Res. 2024 Sep 13;30(18):4100-4114 [PMID: 39047169]
  10. Cancers (Basel). 2023 Nov 02;15(21): [PMID: 37958442]
  11. Pediatrics. 2023 Dec 1;152(6): [PMID: 37920939]
  12. Science. 2019 Mar 15;363(6432):1125 [PMID: 30872493]
  13. J Clin Oncol. 2016 Jan 10;34(2):117-22 [PMID: 26503200]
  14. Nat Rev Cancer. 2014 Jan;14(1):61-70 [PMID: 24304873]
  15. N Engl J Med. 2015 Dec 10;373(24):2336-2346 [PMID: 26580448]
  16. JAMA Netw Open. 2023 Jul 3;6(7):e2325342 [PMID: 37490293]
  17. Clin Pharmacol Ther. 2020 Apr;107(4):786-795 [PMID: 31863465]
  18. Cancer Discov. 2021 Mar;11(3):545-559 [PMID: 33277309]
  19. Pediatr Hematol Oncol. 2022 Apr;39(3):193-202 [PMID: 34665984]
  20. Nat Cancer. 2023 Feb;4(2):203-221 [PMID: 36585449]
  21. Oncotarget. 2018 May 29;9(41):26543-26555 [PMID: 29899875]
  22. Semin Oncol. 2020 Feb;47(1):56-64 [PMID: 32229032]
  23. J Clin Oncol. 2023 Aug 20;41(24):4045-4053 [PMID: 37267580]
  24. J Natl Cancer Inst. 2023 Nov 8;115(11):1337-1354 [PMID: 37433078]

MeSH Term

Humans
Child
Neoplasms
Information Dissemination
Medical Oncology
Biomedical Research
Precision Medicine
Pediatrics

Word Cloud

Created with Highcharts 10.0.0dataresearchpediatriccanceradvancesCCDIsharingclinicaloncologymolecularneedinitiativesInitiativeimprovingstrategiessmallpatientpopulationsCCDI'streatmentoutcomesenablingPURPOSEOFREVIEW:growingemphasisdata-drivenparticularlycontextcharacterizationprecisionmedicineurgentcomprehensivedata-sharingreviewexploresChildhoodCancerDataaddressescriticalRECENTFINDINGS:playskeyroleenhancingintegrationcollaborationMolecularCharacterizationfieldleveragingdetailedinformtrialstherapeuticrhabdomyosarcomaeffortsintegratingacrossinstitutionsvitaladvancingrisk-basedachievemeaningfulSUMMARY:advancementsprofoundimplicationspracticeprecisediagnosestailoringtreatmentsbasedindividualgeneticprofilesaddressingchallengesassociateddrivingtransformativechangesContinuedsupportexpansioncrucialfullyrealizingpotentialchildrenchildhoodinitiative:drivetransformdiagnosis

Similar Articles

Cited By

No available data.